Inhibrx, Inc. (NASDAQ:INBX – Get Rating) Director Jon Faiz Kayyem sold 9,500 shares of the business’s stock in a transaction on Monday, January 23rd. The shares were sold at an average price of $25.26, for a total transaction of $239,970.00. Following the sale, the director now directly owns 3,224,301 shares of the company’s stock, valued at $81,445,843.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Jon Faiz Kayyem also recently made the following trade(s):
- On Wednesday, December 21st, Jon Faiz Kayyem sold 9,500 shares of Inhibrx stock. The stock was sold at an average price of $27.02, for a total transaction of $256,690.00.
- On Monday, November 21st, Jon Faiz Kayyem sold 9,500 shares of Inhibrx stock. The stock was sold at an average price of $29.89, for a total transaction of $283,955.00.
Inhibrx Price Performance
Inhibrx stock traded up $1.27 during trading hours on Monday, reaching $25.45. The stock had a trading volume of 386,242 shares, compared to its average volume of 458,060. The company has a market cap of $1.11 billion, a price-to-earnings ratio of -7.90 and a beta of 3.10. The business’s 50 day moving average price is $26.87 and its 200-day moving average price is $23.86. Inhibrx, Inc. has a 52 week low of $7.67 and a 52 week high of $34.72.
Hedge Funds Weigh In On Inhibrx
Several hedge funds have recently modified their holdings of INBX. Swiss National Bank increased its holdings in Inhibrx by 5.6% in the 1st quarter. Swiss National Bank now owns 22,500 shares of the company’s stock worth $501,000 after buying an additional 1,200 shares during the period. Bank of New York Mellon Corp increased its holdings in Inhibrx by 1.2% in the 1st quarter. Bank of New York Mellon Corp now owns 86,174 shares of the company’s stock worth $1,920,000 after buying an additional 1,017 shares during the period. HighTower Advisors LLC acquired a new position in Inhibrx in the 1st quarter worth approximately $223,000. MetLife Investment Management LLC increased its holdings in Inhibrx by 49.5% in the 1st quarter. MetLife Investment Management LLC now owns 17,227 shares of the company’s stock worth $384,000 after buying an additional 5,704 shares during the period. Finally, Rhumbline Advisers boosted its position in Inhibrx by 13.1% in the 1st quarter. Rhumbline Advisers now owns 28,409 shares of the company’s stock worth $633,000 after purchasing an additional 3,299 shares in the last quarter. Institutional investors and hedge funds own 72.79% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research firms recently weighed in on INBX. Credit Suisse Group lowered their price objective on shares of Inhibrx from $48.00 to $46.00 and set an “outperform” rating for the company in a research note on Tuesday, November 8th. JMP Securities reiterated a “buy” rating and issued a $40.00 target price on shares of Inhibrx in a report on Wednesday, October 5th. Finally, Evercore ISI boosted their target price on shares of Inhibrx from $54.00 to $60.00 and gave the stock an “outperform” rating in a report on Wednesday, October 5th.
Inhibrx Company Profile
Inhibrx, Inc, a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
- Get a free copy of the StockNews.com research report on Inhibrx (INBX)
- Can We Trust The Rally In The S&P 500
- Energy Surge: Four Oil-And-Gas Stocks Setting Up In Bullish Bases
- One ETF Trading Strategy to Beat the Market in 2023
- Is Wayfair Still Way Cheap For Investors?
- When Does Pfizer Become A Bargain?
Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.